What's Behind Regeneron's Stellar Q4 Update

Regeneron Pharmaceuticals (NASDAQ: REGN) is on a roll. Its shares jumped 29% last year. The biotech recently reported very promising results from a late-stage study of its COVID-19 antibody cocktail. The experimental therapy appears to be 100% effective at preventing symptomatic coronavirus infections.

And the roll continues. Regeneron reported its fourth-quarter and full-year 2020 results before the market opened on Friday. Here are the highlights from that update.

Image Source: Getty Images.

Continue reading

Source Fool.com